Jounce Therapeutics, Inc. (JNCE)


+0.06 (+5.31%)
Symbol JNCE
Price $1.19
Beta 0.643
Volume Avg. 1.60M
Market Cap 61.516M
Shares () -
52 Week Range 0.577-8.8
1y Target Est -
DCF Unlevered JNCE DCF ->
DCF Levered JNCE LDCF ->
ROE -58.21% Strong Sell
ROA -64.43% Strong Sell
Operating Margin -
Debt / Equity 22.20% Neutral
P/E -
P/B 0.48 Neutral


Consensus EPS

Upgrades & Downgrades

Latest JNCE news

Dr. Richard Murray
NASDAQ Global Select

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.